Gene Therapy
Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics
Published in Gene Therapy Weekly, October 11th, 2007
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the publication of a key study in the journal Nature by Alnylam and scientists at Roche Kulmbach, together with collaborators from the Swiss Federal Institute of Technology (ETH), UT Southwestern Medical Center at Dallas, and the Massachusetts Institute of Technology (MIT). In the study, acute and repeated dosing of small interfering RNAs (siRNAs), the molecules that mediate RNAi, was found to achieve specific and robust silencing of target genes in vivo without any disruption of the endogenous microRNA pathway.
"An important question in the advancement of RNAi therapeutics has...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-10-11)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
A search for biomarkers for early detection of colorectal cancer - Cancer Gene Therapy
Dr. Andrew I. Schafer Appointed Head of Department of Medicine at NYP/Weill Cornell - Cancer Gene Therapy
Jumping Genes' Could Make for Safer Gene Delivery System - Mental Retardation
Study Reveals Possible Genetic Risk for Fetal Alcohol Disorders - Cancer Gene Therapy
Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers - Acute Leukemia Genetics
New acute leukemia genetics study findings have been reported by researchers at National Cancer Institute - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
